BRISTOL MYERS SQUIBB CO Segments Disclosure
2017 | 2016 | 2015 | |||||||
McKesson Corporation | 24 | % | 22 | % | 21 | % | |||
AmerisourceBergen Corporation | 18 | % | 18 | % | 16 | % | |||
Cardinal Health, Inc. | 15 | % | 14 | % | 12 | % | |||
Revenues | Property, Plant and Equipment | |||||||||||||||||||
Dollars in Millions | 2017 | 2016 | 2015 | 2017 | 2016 | |||||||||||||||
United States | $ | 11,358 | $ | 10,720 | $ | 8,188 | $ | 3,617 | $ | 3,865 | ||||||||||
Europe | 4,988 | 4,215 | 3,491 | 1,266 | 1,003 | |||||||||||||||
Rest of the World(a) | 3,877 | 3,964 | 4,142 | 118 | 112 | |||||||||||||||
Other(b) | 553 | 528 | 739 | — | — | |||||||||||||||
Total | $ | 20,776 | $ | 19,427 | $ | 16,560 | $ | 5,001 | $ | 4,980 | ||||||||||
(a) | Includes Japan which represented 7%, 7% and 10% of total revenues in 2017, 2016 and 2015, respectively. |
(b) | Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations. |
Year Ended December 31, | ||||||||||||
Dollars in Millions | 2017 | 2016 | 2015 | |||||||||
Prioritized Brands | ||||||||||||
Opdivo | $ | 4,948 | $ | 3,774 | $ | 942 | ||||||
Eliquis | 4,872 | 3,343 | 1,860 | |||||||||
Orencia | 2,479 | 2,265 | 1,885 | |||||||||
Sprycel | 2,005 | 1,824 | 1,620 | |||||||||
Yervoy | 1,244 | 1,053 | 1,126 | |||||||||
Empliciti | 231 | 150 | 3 | |||||||||
Established Brands | ||||||||||||
Baraclude | 1,052 | 1,192 | 1,312 | |||||||||
Sustiva Franchise | 729 | 1,065 | 1,252 | |||||||||
Reyataz Franchise | 698 | 912 | 1,139 | |||||||||
Hepatitis C Franchise | 406 | 1,578 | 1,603 | |||||||||
Other Brands | 2,112 | 2,271 | 3,818 | |||||||||
Total Revenues | $ | 20,776 | $ | 19,427 | $ | 16,560 | ||||||
Net product sales | $ | 19,258 | $ | 17,702 | $ | 14,045 | ||||||
Alliance revenues | 1,294 | 1,629 | 2,408 | |||||||||
Other revenues | 224 | 96 | 107 | |||||||||
Total Revenues | $ | 20,776 | $ | 19,427 | $ | 16,560 | ||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2017 | Feb 13, 2018 | Showing above |
| 2016 | Feb 21, 2017 | |
| 2015 | Feb 12, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.